CO2018007112A2 - Composiciones farmacéuticas que comprenden derivados de fenilaminopirimidina - Google Patents
Composiciones farmacéuticas que comprenden derivados de fenilaminopirimidinaInfo
- Publication number
- CO2018007112A2 CO2018007112A2 CONC2018/0007112A CO2018007112A CO2018007112A2 CO 2018007112 A2 CO2018007112 A2 CO 2018007112A2 CO 2018007112 A CO2018007112 A CO 2018007112A CO 2018007112 A2 CO2018007112 A2 CO 2018007112A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical compositions
- compositions
- phenylaminopyrimidine derivatives
- phenylaminopyrimidine
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
RESUMEN Una composición farmacéutica oral que comprende una cantidad efectiva de NRC-AN-019 incluyendo sus sales farmacéuticamente aceptables y sus polimorfos, por la dispersión en un sistema polimérico en un estado final de subdivisión para incrementar la biodisponibilidad oral. También se relaciona con un proceso la preparación de estas composiciones y el uso de dichas composiciones en el tratamiento de Leucemia Mieloide Crónica (LMC) y otros tumores tales como el cáncer de cabeza y cuello, el cáncer de próstata y similares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN6951CH2015 | 2015-12-18 | ||
PCT/IN2016/050035 WO2017103941A1 (en) | 2015-12-18 | 2016-01-30 | Pharmaceutical compositions comprising phenylaminopyrimidine derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018007112A2 true CO2018007112A2 (es) | 2018-07-19 |
Family
ID=59055898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0007112A CO2018007112A2 (es) | 2015-12-18 | 2018-07-09 | Composiciones farmacéuticas que comprenden derivados de fenilaminopirimidina |
Country Status (32)
Country | Link |
---|---|
US (1) | US10383872B2 (es) |
EP (1) | EP3389633B1 (es) |
JP (2) | JP6896738B2 (es) |
KR (1) | KR20180102584A (es) |
CN (1) | CN108495620B (es) |
AU (1) | AU2016373574B2 (es) |
BR (1) | BR112018012458A2 (es) |
CA (1) | CA3008634A1 (es) |
CL (1) | CL2018001590A1 (es) |
CO (1) | CO2018007112A2 (es) |
CY (1) | CY1124580T1 (es) |
DK (1) | DK3389633T3 (es) |
EA (1) | EA036513B1 (es) |
ES (1) | ES2881883T3 (es) |
GB (1) | GB2564262A (es) |
GE (1) | GEP20207176B (es) |
HK (1) | HK1254573A1 (es) |
HR (1) | HRP20211590T1 (es) |
HU (1) | HUE056269T2 (es) |
IL (1) | IL260085B (es) |
LT (1) | LT3389633T (es) |
MA (1) | MA44079B1 (es) |
MX (1) | MX2018007281A (es) |
PH (1) | PH12018501292A1 (es) |
PL (1) | PL3389633T3 (es) |
PT (1) | PT3389633T (es) |
RS (1) | RS62422B1 (es) |
SG (1) | SG11201805142RA (es) |
SI (1) | SI3389633T1 (es) |
UA (1) | UA122592C2 (es) |
WO (1) | WO2017103941A1 (es) |
ZA (1) | ZA201804203B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
CZ2017821A3 (cs) * | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
EP3793527A1 (en) * | 2018-05-14 | 2021-03-24 | Capsugel Belgium NV | Solid dosage forms with high active agent loading |
JP7368548B2 (ja) * | 2021-07-02 | 2023-10-24 | 昊運股▲フン▼有限公司 | 薬学的組成物及びその使用 |
CN115583634B (zh) * | 2022-09-21 | 2023-06-06 | 广东工业大学 | 一种碳氮聚合物材料的制备方法及应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002241268A (ja) * | 2000-12-11 | 2002-08-28 | Takeda Chem Ind Ltd | 水溶解性が改善された医薬組成物 |
EP1786799B1 (en) | 2004-09-09 | 2012-07-04 | Natco Pharma Limited | Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
US8067422B2 (en) | 2008-03-04 | 2011-11-29 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
WO2012002547A1 (ja) * | 2010-07-02 | 2012-01-05 | 富士化学工業株式会社 | ボセンタン固体分散体 |
GB2488788B (en) | 2011-03-07 | 2013-07-10 | Natco Pharma Ltd | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
CN102836159B (zh) * | 2011-06-24 | 2014-12-10 | 南京圣和药业股份有限公司 | 达沙替尼分散体及其制备方法和其在片剂中的应用 |
WO2015095659A2 (en) * | 2013-12-20 | 2015-06-25 | Phosphorex, Inc. | Indirubin solid dispersion composition |
-
2016
- 2016-01-30 ES ES16875074T patent/ES2881883T3/es active Active
- 2016-01-30 MA MA44079A patent/MA44079B1/fr unknown
- 2016-01-30 GB GB1811142.7A patent/GB2564262A/en not_active Withdrawn
- 2016-01-30 HR HRP20211590TT patent/HRP20211590T1/hr unknown
- 2016-01-30 US US16/062,320 patent/US10383872B2/en not_active Expired - Fee Related
- 2016-01-30 CA CA3008634A patent/CA3008634A1/en not_active Abandoned
- 2016-01-30 KR KR1020187020546A patent/KR20180102584A/ko not_active Application Discontinuation
- 2016-01-30 SG SG11201805142RA patent/SG11201805142RA/en unknown
- 2016-01-30 LT LTEPPCT/IN2016/050035T patent/LT3389633T/lt unknown
- 2016-01-30 SI SI201631339T patent/SI3389633T1/sl unknown
- 2016-01-30 EA EA201891443A patent/EA036513B1/ru unknown
- 2016-01-30 JP JP2018532262A patent/JP6896738B2/ja active Active
- 2016-01-30 CN CN201680079960.9A patent/CN108495620B/zh not_active Expired - Fee Related
- 2016-01-30 AU AU2016373574A patent/AU2016373574B2/en not_active Expired - Fee Related
- 2016-01-30 PL PL16875074T patent/PL3389633T3/pl unknown
- 2016-01-30 GE GEAP201614833A patent/GEP20207176B/en unknown
- 2016-01-30 DK DK16875074.3T patent/DK3389633T3/da active
- 2016-01-30 HU HUE16875074A patent/HUE056269T2/hu unknown
- 2016-01-30 EP EP16875074.3A patent/EP3389633B1/en active Active
- 2016-01-30 BR BR112018012458A patent/BR112018012458A2/pt not_active IP Right Cessation
- 2016-01-30 RS RS20211232A patent/RS62422B1/sr unknown
- 2016-01-30 MX MX2018007281A patent/MX2018007281A/es active IP Right Grant
- 2016-01-30 UA UAA201806892A patent/UA122592C2/uk unknown
- 2016-01-30 PT PT168750743T patent/PT3389633T/pt unknown
- 2016-01-30 WO PCT/IN2016/050035 patent/WO2017103941A1/en active Application Filing
-
2018
- 2018-06-14 CL CL2018001590A patent/CL2018001590A1/es unknown
- 2018-06-17 IL IL260085A patent/IL260085B/en unknown
- 2018-06-18 PH PH12018501292A patent/PH12018501292A1/en unknown
- 2018-06-22 ZA ZA2018/04203A patent/ZA201804203B/en unknown
- 2018-07-09 CO CONC2018/0007112A patent/CO2018007112A2/es unknown
- 2018-10-30 HK HK18113869.1A patent/HK1254573A1/zh unknown
-
2020
- 2020-12-03 JP JP2020201322A patent/JP2021059551A/ja not_active Withdrawn
-
2021
- 2021-10-13 CY CY20211100881T patent/CY1124580T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018007112A2 (es) | Composiciones farmacéuticas que comprenden derivados de fenilaminopirimidina | |
BR112017010354B8 (pt) | Compostos de triazolopirimidina, seu uso, e composição farmacêutica | |
CO2017006214A2 (es) | Derivados de quinazolina utilizados para tratar el vih | |
CL2015002628A1 (es) | Compuestos de heteroarilo y sus usos. | |
CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
CO2017001884A2 (es) | Polimorfos de selinexor | |
CL2016001629A1 (es) | Compuestos tricíclicos como agentes anticancerígenos | |
CO2018002829A2 (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) | |
BR112017004448A2 (pt) | uso de agente de reforço de receptor gabaa na preparação de medicamento sedativo e anestésico | |
MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
GT201600269A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
CL2015003195A1 (es) | Derivados de purina como agonistas del receptor cb2. | |
UY36003A (es) | Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina. | |
BR112014016635B8 (pt) | composto, composição, e, uso de um composto | |
UY35359A (es) | 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO | |
CL2015003196A1 (es) | Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2. | |
MY187614A (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
CL2018001085A1 (es) | Derivados de indolin-2-ona | |
CR20160527A (es) | Derivados de carboxamida | |
CO2017005983A2 (es) | Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos | |
TR201819805T4 (tr) | Flavaglin türevleri̇. |